Aslan Pharmaceuticals Executives
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
Aslan Pharmaceuticals employs about 35 people. The company is managed by 7 executives with a total tenure of roughly 14 years, averaging almost 2.0 years of service per executive, having 5.0 employees per reported executive. Analysis of Aslan Pharmaceuticals' management performance can provide insight into the firm performance.
Kiran Asarpota President Vice President-Finance |
Aslan |
Aslan Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.5369) % which means that it has lost $0.5369 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.2664) %, meaning that it created substantial loss on money invested by shareholders. Aslan Pharmaceuticals' management efficiency ratios could be used to measure how well Aslan Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Aslan Pharmaceuticals Workforce Comparison
Aslan Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,076. Aslan Pharmaceuticals claims roughly 35.0 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (2.92) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.91) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.91. Aslan Pharmaceuticals Notable Stakeholders
An Aslan Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aslan Pharmaceuticals often face trade-offs trying to please all of them. Aslan Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aslan Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kiran Asarpota | Vice President-Finance | Profile | |
Alexandre MD | Chief Officer | Profile | |
Stephen Doyle | Chief Officer | Profile | |
Charlie Hsu | Investor Director | Profile | |
ChiChin Wang | IR Director | Profile | |
Ben Goodger | General Counsel | Profile | |
Carl EMBA | CEO Founder | Profile |
About Aslan Pharmaceuticals Management Performance
The success or failure of an entity such as Aslan Pharmaceuticals often depends on how effective the management is. Aslan Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aslan management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aslan management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company was founded in 2010 and is headquartered in Singapore. Aslan Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 27 people.
Aslan Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Aslan Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aslan Pharmaceuticals within its industry.Aslan Pharmaceuticals Manpower Efficiency
Return on Aslan Pharmaceuticals Manpower
Revenue Per Employee | 342.9K | |
Revenue Per Executive | 1.7M | |
Net Loss Per Employee | 1.3M | |
Net Loss Per Executive | 6.3M | |
Working Capital Per Employee | 314.7K | |
Working Capital Per Executive | 1.6M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stocks Directory Find actively traded stocks across global markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |